Monoclonal Antibodies
Ravulizumab for Lupus Nephritis and IgA Nephropathy
This trial is testing the safety and effectiveness of a drug called ravulizumab, given through a vein, in patients with specific kidney diseases. The drug aims to reduce kidney damage by blocking part of the immune system.
Antisense Oligonucleotide
RO7434656 for IgA Nephropathy
This trial is testing a new treatment that uses small genetic pieces to block harmful proteins in people with a specific kidney disease that isn't improving with current treatments. The treatment aims to stop the body from making proteins that make the disease worse.
Popular Filters
Trials for Immunoglobulin A Nephropathy Patients
Endothelin Receptor Antagonist
Atrasentan for IgA Nephropathy
This trial is testing atrasentan, a medication for people with IgA nephropathy (IgAN) who are already on standard treatments. It works by blocking pathways that cause kidney damage, aiming to lower protein levels in the urine. Atrasentan has been previously tested for its effects on albuminuria reduction in patients with type 2 diabetes and nephropathy.
Biological Response Modifier
Atacicept for IgA Nephropathy
This trial is testing a medication called atacicept for people with a kidney disease called IgA Nephropathy who still have too much protein in their urine despite other treatments. Atacicept works by calming the immune system to help reduce protein levels in the urine. The study will compare atacicept to see if it is effective and safe.
Monoclonal Antibodies
BION-1301 for Immunoglobulin A Nephropathy
This trial is testing BION-1301, a medicine that blocks a harmful protein, in adults with IgA nephropathy from a previous study. The medicine helps prevent kidney damage by stopping a specific protein from working.
Endothelin Receptor Antagonist
Atrasentan for IgA Nephropathy
This trial is testing a medication called atrasentan to help people with a kidney disease called IgA nephropathy. It aims to protect their kidneys by reducing protein in their urine. The study will compare atrasentan to another treatment over a few years. Atrasentan has been studied for its effects on reducing protein in urine and protecting kidney function in patients with diabetic nephropathy.
Trials for IgAN Patients
Endothelin Receptor Antagonist
Atrasentan for IgA Nephropathy
This trial is testing atrasentan, a medication for people with IgA nephropathy (IgAN) who are already on standard treatments. It works by blocking pathways that cause kidney damage, aiming to lower protein levels in the urine. Atrasentan has been previously tested for its effects on albuminuria reduction in patients with type 2 diabetes and nephropathy.
Biological Response Modifier
Atacicept for IgA Nephropathy
This trial is testing a medication called atacicept for people with a kidney disease called IgA Nephropathy who still have too much protein in their urine despite other treatments. Atacicept works by calming the immune system to help reduce protein levels in the urine. The study will compare atacicept to see if it is effective and safe.
Monoclonal Antibodies
BION-1301 for Immunoglobulin A Nephropathy
This trial is testing BION-1301, a medicine that blocks a harmful protein, in adults with IgA nephropathy from a previous study. The medicine helps prevent kidney damage by stopping a specific protein from working.
Endothelin Receptor Antagonist
Atrasentan for IgA Nephropathy
This trial is testing a medication called atrasentan to help people with a kidney disease called IgA nephropathy. It aims to protect their kidneys by reducing protein in their urine. The study will compare atrasentan to another treatment over a few years. Atrasentan has been studied for its effects on reducing protein in urine and protecting kidney function in patients with diabetic nephropathy.
Phase 3 Trials
Biological Response Modifier
Atacicept for IgA Nephropathy
This trial is testing a medication called atacicept for people with a kidney disease called IgA Nephropathy who still have too much protein in their urine despite other treatments. Atacicept works by calming the immune system to help reduce protein levels in the urine. The study will compare atacicept to see if it is effective and safe.
Endothelin Receptor Antagonist
Atrasentan for IgA Nephropathy
This trial is testing a medication called atrasentan to help people with a kidney disease called IgA nephropathy. It aims to protect their kidneys by reducing protein in their urine. The study will compare atrasentan to another treatment over a few years. Atrasentan has been studied for its effects on reducing protein in urine and protecting kidney function in patients with diabetic nephropathy.
Trials With No Placebo
Monoclonal Antibodies
BION-1301 for Immunoglobulin A Nephropathy
This trial is testing BION-1301, a medicine that blocks a harmful protein, in adults with IgA nephropathy from a previous study. The medicine helps prevent kidney damage by stopping a specific protein from working.
Immunomodulator
Povetacicept for Autoimmune Kidney Diseases
This trial will assess if a drug (povetacicept) is safe & potentially beneficial in treating IgA nephropathy, membranous nephropathy & lupus nephritis. Participants receive drug every 4 weeks for 6 months, with the possibility of a 6-month extension.
Monoclonal Antibodies
Sibeprenlimab for IgA Nephropathy
This trial is testing the safety and effectiveness of sibeprenlimab, an injectable medication, in patients with IgA Nephropathy who have been part of earlier studies. The medication likely helps manage symptoms or slow disease progression. Sibeprenlimab is being developed as a potential treatment for IgA nephropathy (IgAN).
Frequently Asked Questions
Introduction to iga nephropathy
What are the top hospitals conducting iga nephropathy research?
When it comes to the advancement of medical knowledge and treatment options for Iga nephropathy, there are several hospitals leading the way. Amicis Research Center in Northridge is currently conducting three active clinical trials focused on this condition, showing their commitment to finding new solutions for patients. Interestingly, despite being a relatively new area of research, Amicis Research Center has notched up zero all-time trials in IgA nephropathy—highlighting the importance of ongoing studies in this field. Similarly dedicated to exploring innovative approaches is Kidney Disease Medical Group in Glendale with two ongoing clinical trials specifically targeting IgA nephropathy.
Heading eastward to Denver, Colorado Kidney Care stands out as another prominent institution actively contributing to advancements in understanding and treating IgA nephropathy with two current clinical trials underway. This demonstrates their dedication towards improving patient outcomes through cutting-edge research. Meanwhile, New york Nephrology located in Clifton Park also takes part by hosting two active iga nephropathy investigations; proof that even smaller facilities can make significant impacts on scientific progress within specialized areas.
Last but not least is Academic Medical Research Institute based in Los Angeles where researchers are diligently working on discovering breakthroughs for IgA nephropathy through their own set of two active clinical examinations at present moment.These collective efforts from different locations across the country showcase a united front against this kidney disorder which ultimately affects thousands worldwide.Their endeavor encompasses both well-established institutions and smaller-scale centers paving paths towards better understanding and improved treatments for individuals diagnosed with IgA nephropathy—a testament that progress knows no boundaries when it comes to enhancing healthcare outcomes
Which are the best cities for iga nephropathy clinical trials?
In the realm of Iga nephropathy clinical trials, several cities emerge as frontrunners for research and innovation. Los Angeles, California leads the pack with 11 active trials investigating treatments like Telitacicept 240mg, Atrasentan, and BION-1301. El Paso, Texas follows closely behind with 6 ongoing studies examining interventions such as Telitacicept 240mg and Felzartamab. Northridge, California also boasts 6 active trials focusing on Telitacicept 240mg and BION-1301 among other potential therapies. Lastly, Dallas and Houston in Texas both offer individuals battling IgA nephropathy access to a considerable number of active trials exploring various treatments including Atacicept, sparsentan, and BION-1301 Multiple Doses. These cities serve as critical hubs for advancing knowledge and improving care options for those affected by this condition.
Which are the top treatments for iga nephropathy being explored in clinical trials?
Clinical trials are shedding light on the most promising treatments for Iga nephropathy. Among these, some notable contenders include:
- Budesonide: Currently being investigated in three active clinical trials.
- Rituximab: Garnering attention with two ongoing trials focused on its effectiveness against IgA nephropathy.
- Olokizumab: Showing promise in early-stage research, with one trial currently exploring its potential benefits for patients. These treatments offer hope and hold significant potential for improving outcomes for individuals living with IgA nephropathy.
What are the most recent clinical trials for iga nephropathy?
Recent clinical trials offer hope for individuals with Iga nephropathy, a condition characterized by inflammation in the kidneys. Among these trials is Sequence BA, which is currently in Phase 2 and became available on 7/20/2023. Additionally, BION-1301 has entered Phase 3 as a potential treatment option for IgA nephropathy since becoming available on 6/27/2023. Similarly, Atacicept has also progressed to Phase 3 after its availability on 5/23/2023. These advancements demonstrate ongoing efforts to develop effective interventions that can improve the lives of those affected by this kidney disorder.
What iga nephropathy clinical trials were recently completed?
Recently concluded clinical trials have made significant strides in better understanding and treating Iga nephropathy. Notably, a trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) was completed in November 2021. This study delved into new therapeutic approaches for IgA nephropathy, shedding light on potential advancements in managing this complex kidney disorder. The completion of this trial highlights the ongoing commitment to research that aims to improve outcomes for individuals affected by IgA nephropathy.